Literature DB >> 33130913

Irinotecan-induced intestinal mucositis in mice: a histopathological study.

Thaise Boeing1,2, Marcelo Biondaro Gois3, Priscila de Souza4, Lincon Bordignon Somensi4, Débora de Mello Gonçales Sant Ana5, Luisa Mota da Silva4.   

Abstract

PURPOSE: Intestinal mucositis is an important adverse effect of antineoplastic therapy, which remains without adequate treatment. The present study aimed to carry out a complete evaluation of the histopathological changes during irinotecan-induced intestinal mucositis, using the protocol most found in the pharmacological reports nowadays to better understand irinotecan toxicity and support future studies on drug discovery.
METHODS: Intestinal mucositis was induced by treating swiss mice for 4 days with irinotecan (75 mg/kg, i.p.). After 72 h post irinotecan, the mice were sacrificed and the small intestine and colon were excised to performed histological analysis by stained tissue with hematoxylin/eosin (H&E).
RESULTS: Histoarchitecture loss, villus/crypt ratio reduction, atrophy of the muscular layer, hypertrophy in the submucosal and mucous layers, ruptures in the epithelium, as well as extent cellular infiltrate and presence of micro abscesses and the fusion of the crypts were observed in the histological analysis. Moreover, duodenum and colon had increased intraepithelial lymphocytes and mitotic figures. However, submucosal ganglia were decreased in the duodenum and increased in the colon.
CONCLUSIONS: The data obtained in the present study provides new evidence that irinotecan-induced intestinal mucositis highly affects small intestine and colon, further contributing to establish criteria in light of the histopathological changes induced by irinotecan during intestinal mucositis and facilitating inter-study comparisons.

Entities:  

Keywords:  Chemotherapy; Crypts; Enteric ganglia; Intraepithelial lymphocytes; Morphometric analysis; Villus

Year:  2020        PMID: 33130913     DOI: 10.1007/s00280-020-04186-x

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  16 in total

Review 1.  Regulation and significance of apoptosis in the stem cells of the gastrointestinal epithelium.

Authors:  C S Potten; J W Wilson; C Booth
Journal:  Stem Cells       Date:  1997       Impact factor: 6.277

2.  Carvacryl acetate, a novel semisynthetic monoterpene ester, binds to the TRPA1 receptor and is effective in attenuating irinotecan-induced intestinal mucositis in mice.

Authors:  Elenice M Alvarenga; Nayara A Sousa; Simone de Araújo; José L P Júnior; Alyne R Araújo; Bruno Iles; Dvison M Pacífico; Gerly Anne C Brito; Emmanuel P Souza; Damião P Sousa; Jand Venes R Medeiros
Journal:  J Pharm Pharmacol       Date:  2017-09-21       Impact factor: 3.765

Review 3.  Guidance on the management of diarrhoea during cancer chemotherapy.

Authors:  Jervoise Andreyev; Paul Ross; Clare Donnellan; Elaine Lennan; Pauline Leonard; Caroline Waters; Linda Wedlake; John Bridgewater; Rob Glynne-Jones; William Allum; Ian Chau; Richard Wilson; David Ferry
Journal:  Lancet Oncol       Date:  2014-09       Impact factor: 41.316

4.  The reduction of oxidative stress by nanocomposite Fullerol decreases mucositis severity and reverts leukopenia induced by Irinotecan.

Authors:  Raquel Duque Nascimento Arifa; Talles Prosperi de Paula; Mila Fernandes Moreira Madeira; Renata Lacerda Lima; Zélia Menezes Garcia; Thiago Vinícius Ÿvila; Vanessa Pinho; Lucíola Silva Barcelos; Maurício Veloso Brant Pinheiro; Luiz Orlando Ladeira; Klaus Krambrock; Mauro Martins Teixeira; Danielle Glória Souza
Journal:  Pharmacol Res       Date:  2016-03-15       Impact factor: 7.658

5.  Irinotecan-Induced Gastrointestinal Dysfunction and Pain Are Mediated by Common TLR4-Dependent Mechanisms.

Authors:  Hannah R Wardill; Rachel J Gibson; Ysabella Z A Van Sebille; Kate R Secombe; Janet K Coller; Imogen A White; Jim Manavis; Mark R Hutchinson; Vasiliki Staikopoulos; Richard M Logan; Joanne M Bowen
Journal:  Mol Cancer Ther       Date:  2016-03-29       Impact factor: 6.261

6.  Duodenal histology, ulceration, and Helicobacter pylori in the presence or absence of non-steroidal anti-inflammatory drugs.

Authors:  A S Taha; S Dahill; I Nakshabendi; F D Lee; R D Sturrock; R I Russell
Journal:  Gut       Date:  1993-09       Impact factor: 23.059

7.  Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer.

Authors:  Rachel J Gibson; Joanne M Bowen; Mark R B Inglis; Adrian G Cummins; Dorothy M K Keefe
Journal:  J Gastroenterol Hepatol       Date:  2003-09       Impact factor: 4.029

8.  Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis.

Authors:  Richard M Logan; Rachel J Gibson; Joanne M Bowen; Andrea M Stringer; Stephen T Sonis; Dorothy M K Keefe
Journal:  Cancer Chemother Pharmacol       Date:  2007-08-17       Impact factor: 3.333

9.  Luteolin prevents irinotecan-induced intestinal mucositis in mice through antioxidant and anti-inflammatory properties.

Authors:  Thaise Boeing; Priscila de Souza; Silvia Speca; Lincon Bordignon Somensi; Luisa Nathália Bolda Mariano; Benhur Judah Cury; Mariana Ferreira Dos Anjos; Nara Lins Meira Quintão; Laurent Dubuqoy; Pierre Desreumax; Luisa Mota da Silva; Sérgio Faloni de Andrade
Journal:  Br J Pharmacol       Date:  2020-02-15       Impact factor: 8.739

Review 10.  Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer.

Authors:  Ken-ichi Fujita; Yutaro Kubota; Hiroo Ishida; Yasutsuna Sasaki
Journal:  World J Gastroenterol       Date:  2015-11-21       Impact factor: 5.742

View more
  3 in total

1.  The progression of doxorubicin-induced intestinal mucositis in rats.

Authors:  F Kullenberg; K Peters; C Luna-Marco; A Salomonsson; M Kopsida; O Degerstedt; M Sjöblom; P M Hellström; F Heindryckx; D Dahlgren; H Lennernäs
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-10-22       Impact factor: 3.195

2.  pH-responsive and folate-coated liposomes encapsulating irinotecan as an alternative to improve efficacy of colorectal cancer treatment.

Authors:  Shirleide Santos Nunes; Sued Eustaquio Mendes Miranda; Juliana de Oliveira Silva; Renata Salgado Fernandes; Janaína de Alcântara Lemos; Carolina de Aguiar Ferreira; Danyelle M Townsend; Geovanni Dantas Cassali; Mônica Cristina Oliveira; André Luís Branco de Barros
Journal:  Biomed Pharmacother       Date:  2021-10-08       Impact factor: 7.419

3.  Effects of a novel toll-like receptor 4 antagonist IAXO-102 in a murine model of chemotherapy-induced gastrointestinal toxicity.

Authors:  Janine S Y Tam; Elise E Crame; Aurelia S Elz; Janet K Coller; Anthony Wignall; Clive A Prestidge; Joanne M Bowen
Journal:  Cancer Chemother Pharmacol       Date:  2022-08-12       Impact factor: 3.288

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.